Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

Tetsuhiro Kawata; Naoko Yamamoto; Kyoko Matsushita; Tomoko Naito; Hiroshi Ohtsuki; Makiko Takahashi

Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

Tetsuhiro Kawata, Naoko Yamamoto, Kyoko Matsushita, Tomoko Naito, Hiroshi Ohtsuki, Makiko Takahashi

University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

Original language	English
Pages (from-to)	1457-1460
Number of pages	4
Journal	Japanese Journal of Clinical Ophthalmology
Volume	63
Issue number	9
Publication status	Published - Sep 2009

ASJC Scopus subject areas

Ophthalmology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{cee19259e0b44af78b892cc09d09f06b,

title = "Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma",

abstract = "Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.",

author = "Tetsuhiro Kawata and Naoko Yamamoto and Kyoko Matsushita and Tomoko Naito and Hiroshi Ohtsuki and Makiko Takahashi",

year = "2009",

month = sep,

language = "English",

volume = "63",

pages = "1457--1460",

journal = "Japanese Journal of Clinical Ophthalmology",

issn = "0370-5579",

publisher = "Igaku-Shoin Ltd",

number = "9",

}

TY - JOUR

T1 - Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

AU - Kawata, Tetsuhiro

AU - Yamamoto, Naoko

AU - Matsushita, Kyoko

AU - Naito, Tomoko

AU - Ohtsuki, Hiroshi

AU - Takahashi, Makiko

PY - 2009/9

Y1 - 2009/9

N2 - Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

AB - Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

UR - http://www.scopus.com/inward/record.url?scp=70350337763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350337763&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:70350337763

VL - 63

SP - 1457

EP - 1460

JO - Japanese Journal of Clinical Ophthalmology

JF - Japanese Journal of Clinical Ophthalmology

SN - 0370-5579

IS - 9

ER -

Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this